NeoGenomics (NEO)
Nasdaq Market Closed
NeoGenomics, Inc. is a cancer diagnostics company that provides laboratory testing, pathology interpretation, and related consultative services for oncologists, hospitals, pathology groups, biopharmaceutical companies, and researchers. The company focuses on oncology, where accurate identification of tumor type, genetic alterations, and disease markers can support diagnosis, treatment selection, prognosis, and clinical trial enrollment.
NeoGenomics operates specialized cancer testing laboratories in the United States and the United Kingdom. Its services span traditional cytogenetics, flow cytometry, fluorescence in situ hybridization, immunohistochemistry, molecular testing, and next-generation sequencing. By combining technical laboratory work with professional interpretation by pathologists and molecular experts, the company helps clinicians translate complex test results into information that can be used in patient care.
The company also serves the biopharma and research markets. Its offerings include clinical trial support, assay development and validation, research testing, and oncology data solutions. These capabilities are relevant to drug developers seeking biomarkers, companion diagnostics, or patient stratification tools for targeted cancer therapies.
NeoGenomics operates in a healthcare segment shaped by advances in precision medicine, increasing use of genomic profiling, and the growing complexity of cancer treatment. Demand for its services is tied to oncology testing volumes, reimbursement policies, relationships with clinicians and health systems, and the pace of innovation in targeted therapies and immuno-oncology. Its distinctive position is its concentration on cancer-focused diagnostics rather than broad-based clinical laboratory testing.
Last updated
- Market Cap
- 1.68B
- P/E
- —
- P/FCF
- —
- P/S
- 2.25
- Enterprise Value
- 1.88B
- Sector
- Industrials
- Industry
- Testing Laboratories
- Address
- 9490 NEOGENOMICS WAY, FORT MYERS, FL, 33912
No recent news is linked to this listing.
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 1.68B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 1.88B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 2.03
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 2.25
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -155.86
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 2.51
- EPS
- -0.76
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 74.92
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -5.09M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -11.97%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -7.37%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.41
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 4.42
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 4.06
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 1.73
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 2.4M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 12.9
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 186.67M | 190.17M | 187.8M | 181.33M | 168.04M |
| Gross profit | 80.86M | 83.34M | 80.45M | 77.26M | 73.25M |
| Operating income | -18.24M | -13.41M | -27.01M | -47.63M | -27.83M |
| EBITDA | -1.83M | 3.61M | -3.49M | -10.32M | -10.1M |
| Net income | -17.11M | -9.88M | -27.13M | -45.09M | -25.92M |
| Basic EPS | -0.13 | -0.07 | -0.21 | -0.35 | -0.2 |
| Diluted EPS | -0.13 | -0.07 | -0.21 | -0.35 | -0.2 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 1.35B | 1.36B | 1.37B | 1.39B | 1.6B |
| Total liabilities | 517.77M | 523.27M | 536.49M | 539.91M | 713.16M |
| Total equity | 828.76M | 836.56M | 838.29M | 854.04M | 888.27M |
| Cash & equivalents | 146.14M | 159.62M | 164.12M | 154.72M | 346.19M |
| Current assets | 373.68M | 376.29M | 382.47M | 392.55M | 573.93M |
| Current liabilities | 84.59M | 88.3M | 97.39M | 99.66M | 279.7M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -8.14M | 1.34M | 8.88M | 20.33M | -25.33M |
| Investing cash flow | -5M | -6.31M | -277K | -9.31M | 3.56M |
| Financing cash flow | -338K | 431K | 765K | -202.43M | 949K |
| Change in cash | -13.48M | -4.5M | 9.39M | -191.47M | -20.82M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — NEOGENOMICS INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — NEOGENOMICS INC | View Filing | |
| edgar index | 4 — NEOGENOMICS INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — NEOGENOMICS INC | View Filing | |
| edgar index | 144 — NEOGENOMICS INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| edgar index | 4 — NEOGENOMICS INC | View Filing | |
| edgar index | 144 — NEOGENOMICS INC | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| form 4 | Form 4 — TETRAULT LYNN A. | View Filing | |
| edgar index | 4 — NEOGENOMICS INC | View Filing | |
| edgar index | 4 — NEOGENOMICS INC | View Filing | |
| edgar index | 4 — NEOGENOMICS INC | View Filing | |
| edgar index | 4 — NEOGENOMICS INC | View Filing | |
| edgar index | 4 — NEOGENOMICS INC | View Filing | |
| edgar index | 4 — NEOGENOMICS INC | View Filing | |
| edgar index | 4 — NEOGENOMICS INC | View Filing | |
| edgar index | 4 — NEOGENOMICS INC | View Filing | |
| form 4 | Form 4 — Green Marjorie C | View Filing | |
| form 4 | Form 4 — Green Marjorie C | View Filing | |
| form 4 | Form 4 — Green Marjorie C | View Filing | |
| form 4 | Form 4 — Green Marjorie C | View Filing | |
| form 4 | Form 4 — Green Marjorie C | View Filing | |
| form 4 | Form 4 — Gunn Neil | View Filing | |
| form 4 | Form 4 — Gunn Neil | View Filing | |
| form 4 | Form 4 — Gunn Neil | View Filing | |
| form 4 | Form 4 — Gunn Neil | View Filing | |
| form 4 | Form 4 — Gunn Neil | View Filing | |
| form 4 | Form 4 — Gunn Neil | View Filing | |
| form 4 | Form 4 — Gunn Neil | View Filing | |
| form 4 | Form 4 — KANOVSKY STEPHEN M | View Filing | |
| form 4 | Form 4 — KANOVSKY STEPHEN M | View Filing | |
| form 4 | Form 4 — KANOVSKY STEPHEN M | View Filing | |
| form 4 | Form 4 — KANOVSKY STEPHEN M | View Filing | |
| form 4 | Form 4 — KANOVSKY STEPHEN M | View Filing | |
| form 4 | Form 4 — KANOVSKY STEPHEN M | View Filing | |
| form 4 | Form 4 — KANOVSKY STEPHEN M | View Filing | |
| form 4 | Form 4 — KANOVSKY STEPHEN M | View Filing | |
| form 4 | Form 4 — KANOVSKY STEPHEN M | View Filing | |
| form 4 | Form 4 — KANOVSKY STEPHEN M | View Filing | |
| form 4 | Form 4 — KANOVSKY STEPHEN M | View Filing | |
| form 4 | Form 4 — Kelly Michael Aaron | View Filing | |
| form 4 | Form 4 — Kelly Michael Aaron | View Filing | |
| form 4 | Form 4 — Kelly Michael Aaron | View Filing | |
| form 4 | Form 4 — Kelly Michael Aaron | View Filing | |
| form 4 | Form 4 — Kelly Michael Aaron | View Filing | |
| form 4 | Form 4 — Kelly Michael Aaron | View Filing | |
| form 4 | Form 4 — Kelly Michael Aaron | View Filing | |
| form 4 | Form 4 — Kelly Michael Aaron | View Filing | |
| form 4 | Form 4 — Kelly Michael Aaron | View Filing | |
| form 4 | Form 4 — Kelly Michael Aaron | View Filing |
- Trusted by 1M+ investors
- Global coverage
- Real-time market data
- Independent & unbiased
Join thousands making smarter investment decisions.
Get started for free